Inhibitors such as trametinib, cobimetinib, and binimetinib have been approved by the U.S. Food and Drug Administration for the treatment of BRAF V600E-mutated melanoma, non-small cell lung cancer, and anaplastic thyroid cancer (Lee et al. 2019). This evidence concerns the gene BRAF and melanoma.